Samsung Biologics lands first US manufacturing facility with GSK acquisition

Samsung Biologics will continue supplying products previously manufactured at the site to GSK

Cupid deposits Rs. 82.88 crore for strategic stake in Baazar Style Retail

The deal gives Cupid immediate access to Style Baazar’s fast-growing network of over 260 stores

Senores makes bold US push with new federal-focused JV

Company leadership is framing the move as transformational.

Nuvation Bio secures global rights to promising brain tumor drug Safusidenib, expands Phase 3 study to Japan

BASF Pharma Solutions announces up to 20% price hike on excipients and APIs

The company said the increase—up to 20%—takes effect immediately, or as current contracts allow

PHARMEXCIL Chintan Shivir in Hyderabad charts roadmap to scale India’s pharma exports

Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26

ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses

Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology

Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer

Its a major breakthrough for women’s ovarian cancer care in Europe

Cardinal Health boosts production of cutting-edge cancer therapy ingredient

Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.

Alembic Pharmaceuticals partners with Enthral.ai for learning and training management of its 9000+ learners

Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows

Glenmark Pharmaceuticals accelerates U.S. strategy with direct RYALTRIS distribution

This marks a meaningful step in the company's continued expansion in the region

D2C nutrition brand BeastLife raises Rs 20 crore at Rs 320 crore valuation from GVFL and Equentis

The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years

FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions

The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants

Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients

Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina

Lupin completes acquisition of VISUfarma

The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe

Emcure Pharma reduces Poviztra starting dose price by 55% in India

The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio

Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal

The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions

Rusan unveils APOSAN 3ml multi-dose pen

The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes

VLCC becomes exclusive partner to offer international laser certification exams in India

This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams